Stockscreener 앱 받기
55.12
0.95%
-0.53
시장 영업 전:
55.36
0.24
+0.44%
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
(BMRN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
Janus Henderson High-Yield Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals - ChartMill
BioMarin Pharmaceutical (BMRN) Gains 2.58% as Stock Approaches Key Resistance LevelDiagonal Spread Trade - newsline.com
BMRN Technical Analysis & Stock Price Forecast - Intellectia AI
BioMarin Pharmaceutical's Revenue Guidance Boost Reflects Pipeline Progress and Acquisition GrowthEarnings Cycle Report - newsline.com
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring A 54.74% Potential Upside - DirectorsTalk Interviews
BioMarin (BMRN) up 0.2% since last earnings report: Can it continue? - MSN
10 Most Undervalued Stocks to Buy and Hold for 2 Years - Insider Monkey
BMRN stock down on mixed results from rare disease therapy study - MSN
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN
How BioMarin Pharma is Planning to Grow Their Revenue? - The American Reporter
BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story - Yahoo Finance
BioMarin Pharmaceutical Inc. 2026 8-K Filing Summary: Company Information, Stock Details, and SEC Compliance - Minichart
BioMarin (BMRN) director Athena Countouriotis receives 7,490-share RSU grant - Stock Titan
BioMarin (NASDAQ: BMRN) director receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Maykin Ho receives 7,490 stock units - Stock Titan
Director at BioMarin (NASDAQ: BMRN) awarded 7,490 RSUs - Stock Titan
BioMarin (BMRN) director Mark Enyedy receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Willard H. Dere receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Ian T. Clark awarded 7,490 restricted stock units - Stock Titan
BioMarin (BMRN) director gets 7,490 RSUs, holds 21,045 shares - Stock Titan
BioMarin (BMRN) director receives 7,490 RSUs in stock grant - Stock Titan
BioMarin Shareholders Approve 2026 Governance and Equity Plan - TipRanks
Shareholders of BioMarin (NASDAQ: BMRN) back equity plan and board slate - Stock Titan
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength - Sahm
BioMarin gains on Voxzogo phase 3 results - MSN
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
BioMarin Pharmaceutical Hits Day High with 8.63% Surge in Stock Price - Markets Mojo
Responsive Playbooks and the BMRN Inflection - Stock Traders Daily
BioMarin Pharmaceutical Inc. (BMRN): Analyst Consensus Suggests a 53% Upside for a Biotech Innovator - DirectorsTalk Interviews
BMRN Q1 2026 Earnings: EPS Misses Estimates but Stock Surges 8.63%Earnings Power Value - newsline.com
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development - Insider Monkey
5 Stocks That Could 10X by 2030 - Insider Monkey
Kim Warner Builds Pathways for Early-Career Professionals | BioMarin - BioMarin Pharmaceutical
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside - Investing.com
BioMarin Pharmaceutical (BMRN) Edges Higher as Biotech Sector Shows ResilienceRisk Reward Setups - newsline.com
Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips - Investing.com Nigeria
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
8 New 5-Star Stocks This Week - Morningstar
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results - Sahm
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Navigating a Potential 62.41% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $111 - Moomoo
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Understanding the Setup: (BMRN) and Scalable Risk - Stock Traders Daily
BMRN Maintains Rating by Canaccord Genuity -- Price Target Lowered to $111 - GuruFocus
BioMarin Pharmaceutical Price Target Cut to $111.00/Share From $116.00 by Canaccord Genuity - Moomoo
1.27%
1.43%
자본화:
|
볼륨(24시간):